Login or Join
 Learn then Earn
stockMarketNEWS

 story : Merck scraps two treatments for hospitalized COVID-19 patients, will focus on antiviral for non-hospitalized patients #FinanceUSA #StockMarketNEWS Shares of Merck & Co. were up 0.1% in premarket trading

@stockMarketNEWS Thu 15 Apr, 2021

Posted in: #FinanceUSA #StockMarketNEWS

Merck scraps two treatments for hospitalized COVID-19 patients, will focus on antiviral for non-hospitalized patients #FinanceUSA #StockMarketNEWS
Shares of Merck & Co. were up 0.1% in premarket trading on Thursday after the drug company said the oral antiviral COVID-19 treatment it is developing with Ridgeback Therapeutics did not help hospitalized patients in a mid-stage clinical trial. The companies now plan to test molnupiravir in non-hospitalized COVID-19 patients in a Phase 3 trial, with plans to file for emergency authorization in the second half of the year. They are also planning to see if the experimental therapy works for post-exposure prophylaxis. In a separate news release, Merck said it is discontinuing MK-7110 as a treatment for patients hospitalized with COVID-19, saying that the Food and Drug Administration's request for additional clinical information would push the launch into 2022. "Merck is now focusing its efforts on advancing molnupiravir, which, as an oral medicine for outpatient use, represents a promising potential new approach, and on accelerating production of Johnson & Johnson's COVID-19 vaccine," Dr. Roy Baynes, chief medical officer for Merck Research Laboratories, said in the release. Merck's stock has gained 6.6% since the start of the year, while the broader S&P 500 is up 9.8%.


Munafa USA Munafa India Munafa NSE


Report

Login to follow story

More posts by @stockMarketNEWS

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme